0001628280-24-000744.txt : 20240105
0001628280-24-000744.hdr.sgml : 20240105
20240105195847
ACCESSION NUMBER: 0001628280-24-000744
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240103
FILED AS OF DATE: 20240105
DATE AS OF CHANGE: 20240105
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: O'Brien Patrick
CENTRAL INDEX KEY: 0001627183
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38042
FILM NUMBER: 24518019
MAIL ADDRESS:
STREET 1: 225 S. LAKE AVENUE SUITE 1050
CITY: PASADENA
STATE: CA
ZIP: 91101
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ARROWHEAD PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0000879407
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 460408024
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0930
BUSINESS ADDRESS:
STREET 1: 177 E COLORADO BLVD
STREET 2: SUITE 700
CITY: PASADENA
STATE: CA
ZIP: 91105
BUSINESS PHONE: 626-696-4702
MAIL ADDRESS:
STREET 1: 177 E COLORADO BLVD
STREET 2: SUITE 700
CITY: PASADENA
STATE: CA
ZIP: 91105
FORMER COMPANY:
FORMER CONFORMED NAME: ARROWHEAD RESEARCH CORP
DATE OF NAME CHANGE: 20040112
FORMER COMPANY:
FORMER CONFORMED NAME: INTERACTIVE GROUP INC
DATE OF NAME CHANGE: 20020509
FORMER COMPANY:
FORMER CONFORMED NAME: INTERACTIVE INC
DATE OF NAME CHANGE: 19940224
4
1
wk-form4_1704502718.xml
FORM 4
X0508
4
2024-01-03
0
0000879407
ARROWHEAD PHARMACEUTICALS, INC.
ARWR
0001627183
O'Brien Patrick
177 E. COLORADO BLVD
SUITE 700
PASADENA
CA
91105
0
1
0
0
COO and General Counsel
1
Common Stock
2024-01-03
4
S
0
3849
31.83
D
408726
D
Common Stock
2024-01-03
4
S
0
2800
32.52
D
405926
D
Common Stock
2024-01-03
4
S
0
400
33.41
D
405526
D
Common Stock
2024-01-03
4
S
0
1700
32.65
D
403826
D
Common Stock
2024-01-04
4
S
0
1600
32.63
D
402226
D
Common Stock
2024-01-04
4
A
0
85000
0
A
487226
D
Common Stock
2024-01-05
4
S
0
1900
33.99
D
485326
D
Common Stock
2024-01-05
4
S
0
8200
34.99
D
477126
D
Common Stock
2024-01-05
4
S
0
12741
35.65
D
464385
D
Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
Partial disposition of RSUs to satisfy tax withholding obligations.
The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $31.21 to $32.19, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.
The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $32.22 to $32.91, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $33.10 to $33.76, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
Represents shares underlying restricted stock units with a grant date 01/04/24, which will vest in four equal annual installments.
The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $33.45 to $34.45, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $34.465 to $35.45, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $35.49 to $35.96, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
/s/Patrick O'Brien
2024-01-05